A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction

Ann Surg. 2009 May;249(5):806-13. doi: 10.1097/SLA.0b013e3181a38ed5.

Abstract

Objective: The aim of study was to investigate pharmacological treatment for sinusoidal obstruction syndrome (SOS).

Background: SOS is associated with oxaliplatin-based chemotherapy in patients with hepatic colorectal metastases. Patients with SOS have increased postoperative morbidity after major hepatectomy, but a method for effective prevention of SOS has not been established.

Methods: Male Sprague-Dawley rats were treated with cobalt protoporphyrin IX (CoPP) or olprinone (OLP), a phosphodiesterase III inhibitor, and hepatic HO-1 expression and HO enzymatic activity were determined. Monocrotaline (MCT) was given to rats to induce SOS, and blockage of SOS by CoPP or OLP-induced hepatic HO-1 was examined in these rats. Zinc protoporphyrin IX (ZnPP), a competitive HO inhibitor, was given to MCT-treated rats together with OLP to clarify the mechanism of protection against SOS. We also examined if OLP preserved remnant liver function after 70% hepatectomy in MCT-treated rats.

Results: OLP up-regulated hepatic HO-1 protein expression and HO enzymatic activity, and activated Akt protein. Administration of ZnPP to OLP-treated rats resulted in inhibition of HO activity and inactivation of Akt. Induction of HO-1 by pretreatment with CoPP led to amelioration of SOS in histologic findings and blockage of elevation of serum liver enzymes. Pretreatment with OLP gave a similar result and preserved remnant liver function, as indicated by improved survival after hepatectomy. ZnPP completely abolished the protective effects of OLP.

Conclusions: Protection of the liver from drug-induced injury by prior up-regulation of HO-1 using OLP may have potential as a therapeutic strategy for prevention of SOS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / surgery*
  • Combined Modality Therapy
  • Disease Models, Animal
  • Heme Oxygenase-1 / metabolism*
  • Hepatic Veno-Occlusive Disease / chemically induced
  • Hepatic Veno-Occlusive Disease / prevention & control*
  • Imidazoles / administration & dosage*
  • Liver / drug effects
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery*
  • Male
  • Neoadjuvant Therapy
  • Organoplatinum Compounds / adverse effects
  • Oxaliplatin
  • Phosphodiesterase Inhibitors / administration & dosage*
  • Pyridones / administration & dosage*
  • Rats
  • Rats, Sprague-Dawley
  • Up-Regulation

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Organoplatinum Compounds
  • Phosphodiesterase Inhibitors
  • Pyridones
  • Oxaliplatin
  • olprinone
  • Heme Oxygenase-1